Abstract:BACKGROUND: It is not known whether rigorous intraoperative glycemic control reduces death and morbidity in cardiac surgery patients.OBJECTIVE: To compare outcomes of intensive insulin therapy during cardiac surgery with those of conventional intraoperative glucose management.DESIGN: A randomized, open-label, controlled trial with blinded end point assessment.SETTING: Tertiary care center.PATIENTS: Adults with and without diabetes who were undergoing on-pump cardiac surgery.MEASUREMENTS: The primary outcome was a composite of death, sternal infections, prolonged ventilation, cardiac arrhythmias, stroke, and renal failure within 30 days after surgery. Secondary outcome measures were length of stay in the intensive care unit and hospital.INTERVENTION: Patients were randomly assigned to receive continuous insulin infusion to maintain intraoperative glucose levels between 4.4 (80 mg/dL) and 5.6 mmol/L (100 mg/dL) (n = 199) or conventional treatment (n = 201). Patients in the conventional treatment group were not given insulin during surgery unless glucose levels were greater than 11.1 mmol/L (>200 mg/dL). Both groups were treated with insulin infusion to maintain normoglycemia after surgery.RESULTS: Mean glucose concentrations were statistically significantly lower in the intensive treatment group at the end of surgery (6.3 mmol/L [SD, 1.6] [114 mg/dL {SD, 29}] in the intensive treatment group vs. 8.7 mmol/L [SD, 2.3] [157 mg/dL {SD, 42}] in the conventional treatment group; difference, -2.4 mmol/L [95% CI, -2.8 to -1.9 mmol/L] [-43 mg/dL {CI, -50 to -35 mg/dL}]). Eighty two of 185 patients (44%) in the intensive treatment group and 86 of 186 patients (46%) in the conventional treatment group had an event (risk ratio, 1.0 [CI, 0.8 to 1.2]). More deaths (4 deaths vs. 0 deaths; P = 0.061) and strokes (8 strokes vs. 1 strokes; P = 0.020) occurred in the intensive treatment group. Length of stay in the intensive care unit (mean, 2 days [SD, 2] vs. 2 days [SD, 3]; difference, 0 days [CI, -1 to 1 days]) and in the hospital (mean, 8 days [SD, 4] vs. 8 days [SD, 5]; difference, 0 days [CI, -1 to 0 days]) was similar for both groups.LIMITATIONS: This single-center study used a composite end point and could not examine whether outcomes differed by diabetes status.CONCLUSIONS: Intensive insulin therapy during cardiac surgery does not reduce perioperative death or morbidity. The increased incidence of death and stroke in the intensive treatment group raises concern about routine implementation of this intervention.

[Usefulness and limits of intraoperative hormone measurements in surgery of endocrine duodeno-pancreatic tumors: experience of 72 cases]

Intraoperative intermittently scanned continuous glucose monitoring in the management of patients with pancreatic insulinoma

Retrospective Study on Post-Operative Glucose Level and Insulin Dose in Patients Undergoing Total Pancre-Atectomy

Laparoscope Resection of Retroperitoneal Ectopic Insulinoma: A Rare Case

Intraoperative segmental pancreatic occlusion and insulin assay combination optimizes the localization of lesions and confirmation of complete resection in pancreatic hypoglycemia patients

[Effect of Intensive Insulin Therapy on the Clinical Results of Postoperative Patients with Gastric Cancer].

Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues?

A Systematic Review of the Accuracy of Insulin and C-peptide Secretion Ratios During the Oral Glucose Tolerance Test to Diagnose Insulinoma

Diagnosis and Treatment of Insulinomas: Experience with 62 Clinical Cases

Pancreatic insulinomas: Our 15-year surgical experience

Intraoperative ultrasound in surgery of the pancreas

Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics

Pancreatic beta cell function is preserved in the short term in patients with type 2 diabetes undergoing non-urgent surgery

Intraoperative parathyroid hormone assay benefits surgery for primary hyperparathyroidism when preoperative localisation is negative or not performed

Continuous Blood Glucose Monitoring with Feedback-Controlled Glucose Infusion During Surgical Management of Insulinoma: Report of a Case.

Diagnosis and Surgical Treatment of Functional Insulinomas: Report of 132 Cases

Continuous blood glucose monitoring in insulinoma: report of one case and literature review

Clinical Analysis of InsulinomaThirty-one Cases Report and Literature Review

Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[99mTc]/EDDA)NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma

Localization of pancreatic insulinomas by measurement of serum insulin in hepatic vein after selective intra-arterial calcium stimulation

Intensive Intraoperative Insulin Therapy versus Conventional Glucose Management during Cardiac Surgery